Drug Profile
ARB 1740
Alternative Names: ARB-1740Latest Information Update: 17 Nov 2017
Price :
$50
*
At a glance
- Originator Arbutus Biopharma
- Class Gene therapies; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 24 Oct 2017 Updated pharmacodynamics data from a preclinical trial in Hepatitis B presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
- 03 Oct 2017 Pharmacodynamics data from a preclinical trial in Hepatitis B released by Arbutus Biopharma
- 03 Aug 2017 Arbutus Biopharma completes a phase II trial in Hepatitis B in USA (Parenteral)